目的 研究奧扎格雷聯(lián)合依達(dá)拉奉對(duì)老年腦梗死患者腦水腫及神經(jīng)功能的影響。方法 選擇2013年1月—2016年12月安康市中心醫(yī)院的76例老年腦梗死患者，隨機(jī)分為兩組。對(duì)照組靜脈滴注依達(dá)拉奉注射液治療，每次30 mg，每天2次；觀察組聯(lián)合靜脈滴注注射用奧扎格雷鈉治療，每次80 mg，每天1次。兩組均持續(xù)治療10 d。比較兩組的臨床治療效果，ADL量表評(píng)分以及NIHSS量表評(píng)分，并于治療后對(duì)兩組采取顱腦CT復(fù)查，對(duì)患者的腦水腫程度進(jìn)行分級(jí)評(píng)估。結(jié)果 觀察組的有效率為92.10%，顯著高于對(duì)照組76.32%（P<0.05）。兩組治療10 d后的ADL量表評(píng)分顯著升高（P<0.05），NIHSS量表評(píng)分顯著降低（P<0.05），且觀察組更為明顯，差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。觀察組腦水腫分級(jí)為D級(jí)的發(fā)生率為5.26%，顯著低于對(duì)照組的26.32%（P<0.05）。兩組治療后的血小板聚集率和血黏稠度均降低，且觀察組顯著低于對(duì)照組（P<0.05）。治療后兩組的最大峰值流速以及平均流速均顯著升高（P<0.05），血管阻力指數(shù)以及搏動(dòng)指數(shù)均顯著降低（P<0.05），且觀察組更為明顯，差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 奧扎格雷聯(lián)合依達(dá)拉奉對(duì)老年腦梗死患者明顯優(yōu)于單純使用依達(dá)拉奉，可以有效改善患者的日常生活能力和神經(jīng)功能，緩解腦水腫，且用藥安全性較高，對(duì)患者的預(yù)后具有積極作用。

Objective To investigate the clinical effect ofozagrel combined with edaravone on cerebral edema and neurological function in elderly patients with cerebral infarction.Methods Selected76 cases of patients with cerebral infarction who were treated in our hospital from January 2013toDecember 2016, divided into two groupsrandomly. The control group was treated with intravenous injection of edaravone, and the observation group was treated with intravenous infusion of ozagrel. The clinical treatment effect, ADL scale score and NIHSS scale score were compared between the two groups, and the brain edema degree of patients in the two groups was evaluated by CT examination after treatment. Results After treatment, the effective rate of the observation group was 92.10% (35/38), higher than that of the control group 76.32% (29/38) (P<0.05); the scores of ADL scale in the two groups were significantly increased (P<0.05), and the NIHSS scale score was significantly lower (P<0.05), and the observation group was significantly better than that of the control group (P<0.05). The incidence of cerebral edema grade D in the observation group was 5.26% (2/38), lower than control group 26.32% (10/38) (P<0.05); after treatment, the platelet aggregation rate and blood viscosity of the two groups were significantly decreased (P<0.05), and the decrease in the observation group was more obvious (P<0.05); after treatment, the maximum peak velocity and average flow rate of the two groups were significantly increased (P<0.05), the vascular resistance index and pulsatility index were significantly decreased (P<0.05), and the observation group was more obvious (P<0.05). Conclusion Edaravone combined with ozagrel in elderly patients with cerebral infarction is superior to the single use of edaravone can effectively improve the ability of daily life of patients and nerve function, relieve cerebral edema, and the safety is high, has a positive effect on the prognosis of the patients.